Page last updated: 2024-08-18

pyrroles and sphingosine 1-phosphate

pyrroles has been researched along with sphingosine 1-phosphate in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	4 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hashimoto, T; Igarashi, J; Kosaka, H; Kubota, Y; Miyoshi, M	1
Carrothers, TJ; Inaba, S; Moberly, JB; Rohatagi, S; Shimozato, T; Truitt, KE; Zahir, H	1
Adamowicz, JJ; Berdyshev, EV; Diab, KJ; Garrison, J; Gu, Y; Hubbard, WC; Kamocki, K; Petrache, I; Rajashekhar, G; Rush, NI; Schweitzer, KS; Skobeleva, A	1
Chen, S; Ford, DM; Moberly, JB; Mochizuki, T; Truitt, KE; Vollmer, TL; Zahir, H	1
Cha, SS; Chen, CS; Choi, CK; Galie, PA; Nguyen, DH; Stapleton, SC; Yang, MT	1
Abraham, C; Dulai, PS; Sandborn, WJ; Vermeire, S	1

Reviews

1 review(s) available for pyrroles and sphingosine 1-phosphate

Article	Year
Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2017, Volume: 152, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cytokines; Humans; Inflammatory Bowel Diseases; Interleukin-23; Janus Kinases; Lysophospholipids; Molecular Targeted Therapy; Oligonucleotides; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Smad7 Protein; Sphingosine; Th17 Cells; Transforming Growth Factor beta; Ustekinumab	2017

Article

Year

Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.

Gastroenterology, 2017, Volume: 152, Issue:2

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cytokines; Humans; Inflammatory Bowel Diseases; Interleukin-23; Janus Kinases; Lysophospholipids; Molecular Targeted Therapy; Oligonucleotides; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Smad7 Protein; Sphingosine; Th17 Cells; Transforming Growth Factor beta; Ustekinumab

2017

Trials

1 trial(s) available for pyrroles and sphingosine 1-phosphate

Article	Year
Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator. Journal of clinical pharmacology, 2009, Volume: 49, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Amino Alcohols; CD4-Positive T-Lymphocytes; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Lymphocyte Count; Lymphocyte Subsets; Lymphocytes; Lysophospholipids; Male; Middle Aged; Models, Biological; Prodrugs; Pyrroles; Receptors, Lysosphingolipid; Sphingosine; Young Adult	2009

Article

Year

Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.

Journal of clinical pharmacology, 2009, Volume: 49, Issue:1

Topics: Administration, Oral; Adolescent; Adult; Amino Alcohols; CD4-Positive T-Lymphocytes; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Lymphocyte Count; Lymphocyte Subsets; Lymphocytes; Lysophospholipids; Male; Middle Aged; Models, Biological; Prodrugs; Pyrroles; Receptors, Lysosphingolipid; Sphingosine; Young Adult

2009

Other Studies

4 other study(ies) available for pyrroles and sphingosine 1-phosphate

Article	Year
Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. British journal of pharmacology, 2007, Volume: 150, Issue:4 Topics: Alkyl and Aryl Transferases; Animals; Atorvastatin; Blotting, Western; Cattle; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lysophospholipids; Mevalonic Acid; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Pyrroles; Quinolines; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sphingosine; Stimulation, Chemical	2007
Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema. American journal of respiratory and critical care medicine, 2010, Feb-15, Volume: 181, Issue:4 Topics: Animals; Apoptosis; Blotting, Western; Cells, Cultured; Ceramides; Disease Models, Animal; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Indoles; Lysophospholipids; Mice; Mice, Inbred C57BL; Phosphotransferases (Alcohol Group Acceptor); Polymerase Chain Reaction; Propylene Glycols; Pulmonary Alveoli; Pulmonary Emphysema; Pyrroles; Receptors, Lysosphingolipid; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sphingosine	2010
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients. Journal of neuroimmunology, 2012, May-15, Volume: 246, Issue:1-2 Topics: Administration, Oral; Amino Alcohols; CD4-Positive T-Lymphocytes; Dose-Response Relationship, Immunologic; Down-Regulation; Humans; Lymphocyte Subsets; Lymphopenia; Lysophospholipids; Multiple Sclerosis; Pilot Projects; Pyrroles; Receptors, Lysosphingolipid; Sphingosine	2012
Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2013, Apr-23, Volume: 110, Issue:17 Topics: Biomimetics; Cell Polarity; Dimethylpolysiloxanes; Fingolimod Hydrochloride; Fluorescent Antibody Technique; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Lysophospholipids; Microfluidics; Models, Biological; Morphogenesis; Neovascularization, Physiologic; Propylene Glycols; Pseudopodia; Pyrroles; Sphingosine; Vascular Endothelial Growth Factor Receptor-2	2013